Explore Trades
All Companies

NVOCongressional Stock Trades

Novo Nordisk A/S

Drug Manufacturers - General

Congressional stock trades in Novo Nordisk A/S (NVO) from House and Senate STOCK Act filings. See which members of Congress bought or sold, disclosed amounts, and filing dates.

Total Trades

23

Politicians Trading

7

Last Traded

Sep 10, 2026

Trading History

PartyDemocratRepublican✕
ChamberHouseSenate
TypeBuySell
PoliticianNotifiedTradedTypeAmountChange
Kevin HernRSep 25, 2026Sep 10, 2026Sell$1,001 - $15,000-8.68%
Kevin HernRSep 25, 2026Aug 31, 2026Sell$1,001 - $15,000-11.34%
Scott FranklinRSep 17, 2026Aug 26, 2026Buy$1,001 - $15,000-14.83%
Alan ArmstrongRJul 21, 2026Mar 30, 2026Buy$15,001 - $50,000+13.88%
Lisa C. McClainRNov 21, 2025Oct 31, 2025Sell$1,001 - $15,000-18.74%
Lisa C. McClainRNov 21, 2025Oct 30, 2025Sell$1,001 - $15,000-19.68%
Lisa C. McClainRNov 21, 2025Oct 30, 2025Buy$1,001 - $15,000-19.68%
Lisa C. McClainROct 22, 2025Sep 11, 2025Buy$1,001 - $15,000-25.99%
Marjorie Taylor GreeneROct 20, 2025Oct 15, 2025Buy$1,001 - $15,000-29.14%
Lisa C. McClainRSep 12, 2025Aug 4, 2025Sell$1,001 - $15,000-17.66%
Marjorie Taylor GreeneRAug 29, 2025Aug 28, 2025Buy$1,001 - $15,000-28.37%
Marjorie Taylor GreeneRAug 20, 2025Aug 19, 2025Buy$15,001 - $50,000-26.63%
Scott FranklinRAug 14, 2025Aug 4, 2025Buy$1,001 - $15,000-17.66%
Scott FranklinRAug 14, 2025Aug 4, 2025Buy$1,001 - $15,000-17.66%
Scott FranklinRAug 14, 2025Aug 4, 2025Buy$1,001 - $15,000-17.66%
Scott FranklinRAug 14, 2025Aug 4, 2025Buy$15,001 - $50,000-17.66%
Lisa C. McClainRAug 13, 2025Jul 10, 2025Sell$1,001 - $15,000-43.40%
Lisa C. McClainRAug 13, 2025Jun 9, 2025Buy$1,001 - $15,000-46.74%
Laurel M. LeeRJun 22, 2025May 8, 2025Sell$1,001 - $15,000-38.03%
Byron DonaldsRApr 14, 2025Mar 20, 2025Sell$1,001 - $15,000-48.99%
Byron DonaldsRApr 14, 2025Mar 20, 2025Sell$1,001 - $15,000-48.99%
Scott FranklinRApr 11, 2025Mar 27, 2025Buy$15,001 - $50,000-42.72%
Scott FranklinRApr 11, 2025Mar 27, 2025Buy$1,001 - $15,000-42.72%

Price History

About Novo Nordisk A/S

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products. It operates through two segments, Obesity and Diabetes Care, and Rare Disease. The Obesity and Diabetes care segment provides products for diabetes, obesity, cardiovascular, and other emerging therapy areas. The Rare Disease segment offers products in the areas of rare blood disorders, rare endocrine disorders, and hormone replacement therapy. The company also provides NovoPen 6 and NovoPen Echo Plus, smart insulin pens; Dose Check, an insulin dose guidance application; growth hormone pens and injection needles; and Wegovy pill an oral glucagon-like peptide-1 (GLP-1) receptor agonist therapy for weight management. It operates in Europe, Canada, the United States, Japan, Korea, Oceania, Southeast Asia, Mainland China, Hong Kong and Taiwan, Latin America, the Middle East, and Africa. Novo Nordisk A/S was founded in 1923 and is headquartered in Bagsvaerd, Denmark.

FAQ

7 members of Congress have disclosed 23 trades in Novo Nordisk A/S (NVO). Most active: Lisa C. McClain (7), Scott Franklin (7), Marjorie Taylor Greene (3).

Across all disclosures, members of Congress reported 14 purchases and 9 sales of Novo Nordisk A/S (NVO). The most recent trade was on Sep 10, 2026.

Scott Franklin disclosed buying Novo Nordisk A/S (NVO) on Aug 26, 2026, valued at $1,001 - $15,000.

Kevin Hern disclosed selling Novo Nordisk A/S (NVO) on Sep 10, 2026, valued at $1,001 - $15,000.

From House and Senate periodic transaction reports filed under the STOCK Act. Members of Congress must disclose trades within 45 days, and amounts are reported as ranges, not exact values.